"Welcome to the Piedmont Cancer Institute ("PCI")- not just a place, but your care partner. At PCI our physicians and staff seek to understand and treat the whole patient. When faced with the fact that the word "cancer" has entered the life of a patient and their family, a flood of images and emotions present themselves. At PCI, we see each patient as an individual and each circumstance as unique. When you choose PCI as your partner in your cancer journey, you can expect the best possible care, using leading edge cancer therapies, participation in clinical trials accessing newly developed cancer treatments and the extensive resources of the Piedmont Cancer Center and its comprehensive cancer treatment team."

During the past decade, Piedmont Cancer Institute conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 25 clinical trials were completed, i.e. on average, 64.1% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 16 clinical trials were completed. i.e. 123.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Piedmont Cancer Institute" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Genentech, Inc." with 5 trials sponsored, "Gilead Sciences" with 4 trials sponsored, "Celgene" with 3 trials sponsored and "Daiichi Sankyo, Inc." with 3 trials sponsored. Other sponsors include 47 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Piedmont Cancer Institute" #1 collaborator was "AstraZeneca" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Bayer" with 3 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator and "Cancer Research UK" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Piedmont Cancer Institute" are "Breast Cancer" (12 trials), "Prostate Cancer" (6 trials), "Bladder Cancer" (4 trials), "Metastatic Breast Cancer" (4 trials) and "Chronic Lymphocytic Leukemia" (3 trials). Many other conditions were trialed in "Piedmont Cancer Institute" in a lesser frequency.

Most popular intervention types in "Piedmont Cancer Institute" are "Drug" (64 trials), "Biological" (10 trials), "Other" (3 trials), "Device" (2 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Carboplatin" (6 trials), "Gemcitabine" (6 trials), "Paclitaxel" (5 trials) and "Pembrolizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Piedmont Cancer Institute" are 56 trials for "All" genders, 11 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Piedmont Cancer Institute". undefined are not yet recruiting, 8 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in Piedmont Cancer Institute, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Piedmont Cancer Institute, 13 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Piedmont Cancer Institute has several departments that took part in Clinical trials: "Piedmont Cancer Institute - Atlanta,775 Poplar Road" - 6 trials, "Piedmont Cancer Institute, PC" - 5 trials